A new report reveals alarming trends in childhood health, linking rising chronic diseases to ultra-processed foods and a lack of physical activity. Are we failing our children?
A new study reveals that a healthier diet can lead to later onset of menarche, potentially reducing the risk of chronic diseases in women. Discover how what you eat impacts your menstrual health.
Recent clinical trials show that GLP-1 weight loss medications like Zepbound are more effective for women than men, prompting researchers to explore the biological and societal reasons behind this phenomenon.
New research reveals that silencing hyperactive AgRP neurons in the brain could reverse type 2 diabetes without affecting weight or diet. This groundbreaking study challenges existing beliefs and points to new treatment avenues.
In a surprising move, Lars Fruergaard Jørgensen is stepping down as CEO of Novo Nordisk after years of leading the company through a successful phase in obesity and diabetes medications. As the search for his successor begins, what does this mean for the future of the pharmaceutical giant?
In a surprising move, Novo Nordisk CEO Lars Fruergaard Jorgensen steps down as the company faces significant market challenges and competition from Eli Lilly's Zepbound. With share prices plummeting, the board seeks new leadership to navigate the turbulent landscape.
In a groundbreaking clinical trial, Mounjaro proves to be nearly 50% more effective than Ozempic. This article explores the implications of this major breakthrough in weight loss treatments.
Discover why Americans are getting heavier despite advancements in fitness. Nutritionist Autumn Bates reveals four key reasons related to diet, activity, and sleep that explain the obesity epidemic.
A landmark study reveals that weight-loss injections may significantly reduce the risk of obesity-related cancers, potentially transforming preventive medicine. The findings suggest that GLP-1 receptor agonists could halve cancer risk, prompting calls for further research.
A groundbreaking trial reveals that Mounjaro is more effective than Wegovy for weight loss, achieving a 20% reduction over 72 weeks compared to Wegovy's 14%. Discover the implications for obesity treatment!
